AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A compound of Formula (I):



(I)

wherein Q is:



(IIa)

or



(IIb)

R_1 is selected from the group consisting of:

(i) C_{1-16} alkyl, and

C_{1-16} alkyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•hydroxy,

•oxo,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

••carbocyclic aryl,

••heterocyclyl, and

••heterocyclyl substituted by C_{1-5} alkyl,

•C_{1-5} alkylcarbonyloxy,

•carbocyclyloxy,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••nitro,

••cyano,

••amino,

••carbocyclic aryl,

••carbocyclic aryl substituted by C_{1-5} alkoxy,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy,

•••carboxy,

•••oxo,

•••mono-C_{1-5} alkylamino,

•••di-C_{1-5} alkylamino,

•••mono-C_{1-5} alkylamino substituted by carbocyclic aryl,

•••di-C_{1-5} alkylamino substituted by carbocyclic aryl,

•••mono-C_{1-5} alkylamino substituted by halogenated carbocyclic aryl,

•••di-C_{1-5} alkylamino substituted by halogenated carbocyclic aryl,

•••carbocyclic arylcarbonylamino, and

•••carbocyclic arylcarbonylamino substituted by halogen,

•heterocyclyloxy,

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••nitro,

••cyano,

••amino,

••carbocyclic aryl,

••carbocyclic aryl substituted by C_{1-5} alkoxy,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

•substituted heterocyclyl-ethylideneaminooxy,

•C_{1-5} alkoxycarbonyl,

•C_{1-5} alkoxycarbonyl substituted by carbocyclic aryl,

•mono-C_{1-5} alkylaminocarbonyl,

•di-C_{1-5} alkylaminocarbonyl,

•mono-C_{1-5} alkylamino,

•mono-C_{1-5} alkylamino substituted by substituent(s) independently selected from the group consisting of:

••cyano,

••carbocyclic aryl, and

••heterocyclyl,

•di-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino substituted by substituent(s) independently selected from the group consisting of:

••cyano,

••carbocyclic aryl, and

••heterocyclyl,

•mono-carbocyclic arylamino,

•mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••nitro,

••cyano,

••amino,

••carbocyclic aryl,

••carbocyclic aryl substituted by C_{1-5} alkoxy,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

•di-carbocyclic arylamino,

•di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••nitro,

••cyano,

••amino,

••carbocyclic aryl,

••carbocyclic aryl substituted by C_{1-5} alkoxy,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

•mono-heterocyclylamino,

•mono-heterocyclylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••nitro,

••cyano,

••amino,

••carbocyclic aryl,

••carbocyclic aryl substituted by C_{1-5} alkoxy,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

•di-heterocyclylamino,

•di-heterocyclylamino substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••nitro,

••cyano,

••amino,

••carbocyclic aryl,

••carbocyclic aryl substituted by C_{1-5} alkoxy,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy, and

•••carboxy,

•C_{1-5} alkylcarbonylamino,

•C_{1-5} alkylcarbonylamino substituted by substituent(s) independently selected from the group consisting of:

••C_{1-5} alkylcarbonylamino,

••carbocyclic arylcarbonylamino, and

••heterocyclyl,

•C_{1-5} alkoxycarbonylamino,

•carbocyclic arylcarbonylamino,

•heterocyclyl carbonylamino,

•carbocyclic arylsulfonylamino,

•carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from the group consisting of:

••nitro,

••C_{1-5} alkyl,

••mono-C_{1-5} alkylamino, and

••di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by substituent(s) independently selected from the group consisting of:

••mono-carbocyclic arylaminocarbonyl,

••mono-carbocyclic arylaminocarbonyl substituted by halogen,

••di-carbocyclic arylaminocarbonyl,

••di-carbocyclic arylaminocarbonyl substituted by halogen,

••mono-carbocyclic arylamino,

••mono-carbocyclic arylamino substituted by halogen,

••di-carbocyclic arylamino,

••di-carbocyclic arylamino substituted by halogen,

••carbocyclic aryl, and

••carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•••halogen, and

•••C_{1-5} alkoxy,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by halogen,

•carbocyclic arylsulfinyl,

•carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by halogen,

•carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by halogen,

•heterocyclylthio,

•heterocyclylthio substituted by substituent(s) independently selected from the group consisting of:

••nitro, and

••C_{1-5} alkyl,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkyl substituted by C_{1-5} alkyl,

•C_{3-6} cycloalkyl substituted by carbocyclic aryl,

•C_{3-6} cycloalkenyl,

•carbocyclyl,

•carbocyclyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkoxy,

••C_{2-5} alkenyl, and

••C_{2-5} alkenyl substituted by substituent(s) independently selected from the group consisting of:

•••carbocyclic aryl, and

•••carbocyclic aryl substituted by C_{1-5} alkylsulfinyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••cyano,

••nitro,

••amino,

••C_{1-5} alkylcarbonylamino,

••C_{3-6} cycloalkylcarbonylamino,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy,

•••carboxy,

•••carbamoyl,

•••oxo,

•••carbocyclic aryl,

•••heterocyclyl,

•••mono-carbocyclic arylamino,

•••di-carbocyclic arylamino,

•••mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••••halogen,

••••nitro,

••••C_{1-5} alkyl,

••••C_{1-5} alkoxy, and

••••C_{1-5} alkoxy substituted by halogen,

•••di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

••••halogen,

••••nitro,

••••C_{1-5} alkyl,

••••C_{1-5} alkoxy, and

••••C_{1-5} alkoxy substituted by halogen,

••C_{2-5} alkenyl,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by substituent(s) independently selected from the group consisting of:

•••halogen, and

•••carbocyclic aryl,

••carbocyclic aryloxy,

••C_{1-5} alkoxycarbonyl,

••C_{1-5} alkylcarbonyloxy,

••mono-C_{1-5} alkylamino,

••di-C_{1-5} alkylamino,

••mono-carbocyclic arylamino,

••mono-carbocyclic arylamino substituted by halogen,

••di-carbocyclic arylamino,

••di-carbocyclic arylamino substituted by halogen,

••mono-carbocyclic arylaminocarbonyl,

••mono-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

•••halogen,

•••nitro,

•••C_{1-5} alkyl,

•••C_{1-5} alkoxy, and

•••C_{1-5} alkoxy substituted by halogen,

••di-carbocyclic arylaminocarbonyl,

••di-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

•••halogen,

•••nitro,

•••C_{1-5} alkyl,

•••C_{1-5} alkoxy, and

•••C_{1-5} alkoxy substituted by halogen,

••mercapto,

••C_{1-5} alkylthio,

••C_{1-5} alkylthio substituted by halogen,

••C_{1-5} alkylsulfonyl,

••C_{3-6} cycloalkyl,

••carbocyclic aryl, and

••heterocyclyl,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••cyano,

••nitro,

••amino,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy,

•••carboxy, and

•••carbamoyl,

••C_{1-5} alkyl substituted by carbocyclic aryl,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen,

••C_{1-5} alkoxy substituted by carbocyclic aryl,

••carbocyclic aryl, and

••carbocyclic aryl substituted by halogen,

(ii) C_{2-8} alkenyl, and

C_{2-8} alkenyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•oxo,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by carbocyclic aryl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••nitro,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••hydroxy,

••nitro,

••C_{1-5} alkyl, and

••C_{1-5} alkoxy,

(iii) C_{2-5} alkynyl, and

C_{2-5} alkynyl substituted by carbocyclic aryl,

(iv) C_{3-12} cycloalkyl, and

C_{3-12} cycloalkyl substituted by substituent(s) independently selected from the group consisting of:

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

••hydroxy,

••oxo, and

••carbocyclic aryl,

•mono-C_{1-5} alkylamino,

•mono-C_{1-5} alkylamino substituted by carbocyclic aryl,

•di-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino substituted by carbocyclic aryl,

•carbocyclic arylcarbonylamino,

•carbocyclic aryl, and

•carbocyclic aryl substituted by halogen,

(v) C_{3-6} cycloalkenyl, and

C_{3-6} cycloalkenyl substituted by C_{1-5} alkyl,

(vi) carbocyclyl, and

carbocyclyl substituted by substitutent(s) independently selected from the group consisting of:

•hydroxy, and

•nitro,

(vii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•hydroxy,

•cyano,

•nitro,

•C_{1-10} alkyl,

•C_{1-10} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••oxo,

••C_{1-5} alkoxy,

••carbocyclic aryloxy,

••mono-C_{1-5} alkylamino-N-oxy,

••di-C_{1-5} alkylamino-N-oxy,

••mono-C_{1-5} alkylamino,

••di-C_{1-5} alkylamino,

••mono-C_{1-5} alkylamino substituted by carbocyclic aryl,

••di-C_{1-5} alkylamino substituted by carbocyclic aryl,

••mono-carbocyclic arylamino,

••di-carbocyclic arylamino,

••carbocyclylimino,

••carbocyclylimino substituted by carbocyclic aryl,

••mono-carbocyclic arylamino,

••di-carbocyclic arylamino,

••mono-carbocyclic arylamino substituted by C_{1-5} alkoxy,

••di-carbocyclic arylamino substituted by C_{1-5} alkoxy,

••mono-carbocyclic arylaminocarbonyl,

••di-carbocyclic arylaminocarbonyl,

••mono-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkoxy,

••di-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkoxy,

••carbocyclic aryl,

••carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl, and

•••C_{1-5} alkyl substituted by halogen,

••heterocyclyl, and

••heterocyclyl substituted by C_{1-5} alkyl,

•C_{2-5} alkenyl,

•C_{2-5} alkenyl substituted by carbocyclic aryl,

•C_{1-9} alkoxy,

•C_{1-9} alkoxy substituted by substituent(s) independently selected from the group consisting of:

••hydroxy,

••halogen,

••carboxy,

••mono-C_{1-5} alkylamino,

••di-C_{1-5} alkylamino,

••carbocyclic aryl,

••halogenated carbocyclic aryl,

••heterocyclyl,

••heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••heterocyclyl, and

•••heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••••halogen,

••••C_{1-5} alkyl, and

••••C_{1-5} alkyl substituted by halogen,

•C_{2-5} alkenyloxy,

•C_{3-6} cycloalkoxy,

•C_{1-5} alkylcarbonyloxy,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••cyano,

••nitro,

••amino,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy,

•••carboxy, and

•••carbamoyl,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•heterocyclyloxy,

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••cyano,

••nitro,

••amino,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy,

•••carboxy, and

•••carbamoyl,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•(carbocyclic aryl)$S(O)_2O$,

•carboxy,

•carbamoyl,

•C_{1-5} alkoxycarbonyl,

•mono-C_{1-5} alkylaminocarbonyl,

•di-C_{1-5} alkylaminocarbonyl,

•mono-C_{1-5} alkylaminocarbonyl substituted by carbocyclic aryl,

•di-C_{1-5} alkylaminocarbonyl substituted by carbocyclic aryl,

•mono-carbocyclic arylaminocarbonyl,

•di-carbocyclic arylaminocarbonyl,

•mono-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkyl,

•di-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkyl,

•amino,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•mono-C_{1-5} alkylamino substituted by cyano,

•di-C_{1-5} alkylamino substituted by cyano,

•mono-carbocyclic arylamino,

•di-carbocyclic arylamino,

•C_{1-5} alkylcarbonylamino,

•C_{3-6} cycloalkylcarbonylamino,

•C_{2-5} alkynylcarbonylamino,

•C_{2-5} alkynylcarbonylamino substituted by carbocyclic aryl,

•C_{1-5} alkoxycarbonylamino,

•carbocyclic arylsulfonylamino,

•carbocyclic arylsulfonylamino substituted by C_{1-5} alkyl,

•(carbocyclic aryl)NHC(O)NH,

•(carbocyclic aryl)NHC(O)NH substituted by C_{1-5} alkoxy,

•(carbocyclic aryl)NHC(O)NH substituted by haloganated C_{1-5} alkoxy,

•carbocyclic aryl azo,

•carbocyclic aryl azo substituted by mono-C_{1-5} alkylamino,

•carbocyclic aryl azo substituted by di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by halogen,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••cyano, and

••C_{1-5} alkyl,

•aminosulfonyl,

•heterocyclylthio,

•C_{1-5} alkylsulfonyl,

•mono-C_{1-5} alkylaminosulfonyl,

•di-C_{1-5} alkylaminosulfonyl,

•heterocyclylsulfonyl,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkyl substituted by C_{1-5} alkyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••C_{1-7} alkyl, and

••C_{1-7} alkyl substituted by halogen,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••C_{1-5} alkyl,

••carbocyclic aryl, and

••halogenated carbocyclic aryl,

•C_{1-5} alkoxycarbonyl substituted by carbocyclic aryl, and

(viii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•hydroxy,

•carboxy,

•carbamoyl,

•cyano,

•nitro,

•amino,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••hydroxy,

••carboxy,

••carbamoyl,

••oxo,

••C_{1-5} alkylcarbonyloxy,

••carbocyclic arylcarbonylamino,

••carbocyclic arylcarbonylamino substituted by halogen,

••C_{1-5} alkoxycarbonyl,

••C_{1-5} alkylthio,

••C_{1-5} alkylthio substituted by carbocyclic aryl,

••C_{1-5} alkylthio substituted by halogenated carbocyclic aryl,

••carbocyclic aryl,

••carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•••halogen, and

•••nitro,

••heterocyclyl, and

••heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl, and

•••C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by halogen,

•C_{1-5} alkoxy substituted by carbocyclic aryl,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••cyano,

••hydroxy,

••carboxy,

••carbamoyl,

••amino,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy,

•••carboxy, and

•••carbamoyl,

••mono-C_{1-5} alkylamino,

••di-C_{1-5} alkylamino,

••C_{1-5} alkylcarbonylamino,

••C_{3-6} cycloalkycarbonylamino,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen,

••C_{3-6} cycloalkyl,

••C_{2-5} alkenyl,

••C_{2-5} alkynyl,

••carboxy,

••C_{1-5} alkoxycarbonyl,

••mono-C_{1-5} alkylaminocarbonyl,

••di-C_{1-5} alkylaminocarbonyl,

••mono-C_{3-6} cycloalkylaminocarbonyl,

••di-C_{3-6} cycloalkylaminocarbonyl,

••mono-C_{1-5} alkylaminocarbonylamino,

••di-C_{1-5} alkylaminocarbonylamino,

••mono-C_{3-6} cycloalkylaminocarbonylamino,

••di-C_{3-6} cycloalkylaminocarbonylamino,

••C_{1-5} alkylthio,

••C_{1-5} alkylthio substituted by halogen,

••C_{1-5} alkylsulfinyl,

••C_{1-5} alkylsulfinyl substituted by halogen,

••C_{1-5} alkylsulfonyl, and

••C_{1-5} alkylsulfonyl substituted by halogen,

•heterocyclyloxy,

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••hydroxy,

••carboxy,

••carbamoyl,

••cyano,

••amino,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••hydroxy,

•••carboxy, and

•••carbamoyl,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{1-5} alkylcarbonylamino,

•C_{1-5} alkylthio,

•C_{2-5} alkenylthio,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by halogen,

•carbocyclic arylthio substituted by C_{1-5} alkoxycarbonyl,

•heterocyclylthio,

•heterocyclylthio substituted by C_{1-5} alkyl,

•C_{1-5} alkylsulfinyl,

•C_{1-5} alkylsulfonyl,

•carbocyclic arylsulfinyl,

•carbocyclic arylsulfinyl substituted by halogen,

•carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by halogen,

•carbocyclic arylsulfonyl substituted by C_{1-5} alkyl,

•C_{1-5} alkoxycarbonyl,

•C_{1-5} alkoxycarbonyl substituted by carbocyclic aryl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxycarbonyl;

R_2 is halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, C_{1-5} alkyl substituted by hydroxy, C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by halogenated carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{1-5} alkyl substituted by halogenated heterocyclyl, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-5} alkoxy, C_{1-5} alkoxy substituted by halogen, C_{1-5} alkylthio, $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently hydrogen, C_{1-5} alkyl, or C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•hydroxy,

•carboxy,

•carbamoyl,

•C_{1-5} alkoxy,

•amino,

•C_{3-6} cycloalkyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkoxy,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy substituted by halogen, and

- -SO_2NH_2,

- heterocyclyl, and

- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

  - halogen,

  - C_{1-5} alkyl,

  - C_{1-5} alkoxy,

  - C_{1-5} alkyl substituted by halogen, and

  - C_{1-5} alkoxy substituted by halogen,

C_{3-6} cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- halogen,

- C_{1-5} alkyl,

- C_{1-5} alkoxy,

- C_{1-5} alkyl substituted by halogen, and

- C_{1-5} alkoxy substituted by halogen,

heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,

- C_{1-5} alkyl,

- C_{1-5} alkoxy,

- C_{1-5} alkyl substituted by halogen, and

- C_{1-5} alkoxy substituted by halogen;

L is selected from the group consisting of Formulae (III), (IIIa), (IIIb), (IV), (IVa), and (IVb);



(III)



(IIIa)



(IIIb)



(IV)



(IVa)



(IVb)

wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-CH_2-$, or $-(CH_2)_2-$;

Z_1, Z_2, Z_3, and Z_4 are each independently hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, C_{1-5} alkyl substituted by hydroxy, C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by halogenated carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{1-5} alkyl substituted by halogenated heterocyclyl, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{3-6} cycloalkyl, C_{1-5} alkoxy, C_{1-5} alkoxy substituted by halogen, mono-C_{1-5} alkyl amino, di-C_{1-5} alkyl amino, C_{1-5} alkylthio, carbocyclic aryl, substituted carbocyclic aryl, heterocyclyl, or substituted heterocyclyl; or

R_2 and Z_2 are bonded to each other to form a ring and $-R_2-Z_2-$ is $-(CH_2)n-$ or $-(CH_2)o-CH=CH-(CH_2)p-$; wherein one $-CH_2-$ group of $-R_2-Z_2-$ can optionally be replaced by C(O), NR_6, O, S, S(O), or $S(O)_2$; wherein n is 2, 3, 4, 5, or 6; o and p are each independently 0, 1, 2, 3, or 4 provided that o+p = 0, 1, 2, 3, or 4; and R_6 is hydrogen, C_{1-5} alkyl, or substituted C_{1-5} alkyl;

and

Y represents:

(i) $-C(O)NR_5-$, $-C(S)NR_5-$, $-C(O)O-$, $-S(O)_2-$, $-C(O)-$, $-C(S)-$, or $-(CH_2)_m-$ when L is selected from the group consisting of Formulae (III), (IIIa), and (IIIb); or

(ii) $-C(O)NR_5-$, $-C(S)NR_5-$, $-C(O)O-$, or $-OC(O)-$ when L is selected from the group consisting of Formulae (IV), (IVa), and (IVb);

wherein R_5 is hydrogen or C_{1-5} alkyl; and m is 0, 1, 2, 3, 4, or 5;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, phenanthryl, or biphenyl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, indenyl, menthyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]heptenyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolo[2,3-c]pyridyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,2',5',2''-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, 4*H*-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidinyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,1-b]thiazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl;

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

2. ***(original):*** The compound according to claim 1 wherein Q is Formula (IIa);

Z_1 is hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, C_{3-6} cycloalkyl, C_{1-5} alkoxy, C_{1-5} alkoxy substituted by halogen, or C_{1-5} alkylthio; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

3. ***(original):*** The compound according to claim 2 wherein R_1 is selected from the group consisting of:

(i) C_{1-10} alkyl, and

C_{1-10} alkyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•oxo,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by carbocyclic aryl,

•C_{1-5} alkylcarbonyloxy,

•C_{1-5} alkoxycarbonyl,

•C_{1-5} alkoxycarbonyl substituted by carbocyclic aryl,

•carbocyclic aryloxy, and

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by oxo,

•heterocyclyloxy,

•heterocyclyloxy substituted by C_{1-5} alkyl,

•mono-carbocyclic arylamino,

•di-carbocyclic arylamino,

•carbocyclic arylsulfonylamino,

•carbocyclic arylsulfonylamino substituted by C_{1-5} alkyl,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by carbocyclic aryl,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by halogen,

•carbocyclic arylthio substituted by C_{1-5} alkyl,

•carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by halogen,

•heterocyclylthio,

•heterocyclylthio substituted by C_{1-5} alkyl,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkenyl,

•carbocyclyl,

•carbocyclyl substituted by C_{1-5} alkoxy,

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••carbocyclic aryl, and

•••heterocyclyl,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen,

••C_{1-5} alkoxy substituted by carbocyclic aryl,

••carbocyclic aryloxy,

••mono-carbocyclic arylaminocarbonyl, and

••mono-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl,

•••C_{1-5} alkoxy, and

•••C_{1-5} alkoxy substituted by halogen,

••di-carbocyclic arylaminocarbonyl, and

••di-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl,

•••C_{1-5} alkoxy, and

•••C_{1-5} alkoxy substituted by halogen,

••C_{1-5} alkylthio,

••C_{1-5} alkylthio substituted by halogen,

••C_{1-5} alkylsulfonyl,

••carbocyclic aryl, and

••heterocyclyl,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••C_{1-5} alkyl,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by carbocyclic aryl,

••carbocyclic aryl, and

••carbocyclic aryl substituted by halogen,

(ii) C_{2-5} alkenyl, and

C_{2-5} alkenyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••nitro,

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

(iii) C_{3-6} cycloalkyl, and

C_{3-6} cycloalkyl substituted by substituent(s) independently selected from the group consisting of:

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by carbocyclic aryl,

•carbocyclic arylcarbonylamino, and

•carbocyclic aryl,

(iv) carbocyclyl, and

carbocyclyl substituted by nitro,

(v) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•cyano,

•nitro,

•C_{1-9} alkyl, and

•C_{1-9} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••oxo,

••mono-carbocyclic arylaminocarbonyl,

••di-carbocyclic arylaminocarbonyl,

••mono-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkoxy,

••di-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkoxy,

••carbocyclic aryloxy,

••carbocyclic aryl, and

••carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

••• C_{1-5} alkyl, and

••• C_{1-5} alkyl substituted by halogen,

••heterocyclyl, and

••heterocyclyl substituted by C_{1-5} alkyl,

• C_{2-5} alkenyl,

• C_{1-7} alkoxy,

• C_{1-7} alkoxy substituted by halogen,

• C_{1-7} alkoxy substituted by carbocyclic aryl,

• C_{3-6} cycloalkoxy,

•carbocyclic aryloxy, and

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro, and

•• C_{1-5} alkoxy

•heterocyclyloxy, and

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxycarbonyl,

•mono-C_{1-5} alkylaminocarbonyl,

•di-C_{1-5} alkylaminocarbonyl,

•mono-C_{1-5} alkylaminocarbonyl substituted by carbocyclic aryl,

•di-C_{1-5} alkylaminocarbonyl substituted by carbocyclic aryl,

•mono-carbocyclic arylaminocarbonyl,

•di-carbocyclic arylaminocarbonyl,

•mono-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkyl,

•di-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkyl,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by halogen,

•C_{1-5} alkylsulfonyl,

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••C_{1-7} alkyl, and

••C_{1-7} alkyl substituted by halogen,

(vi) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl, and

•C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••oxo,

••carbocyclic aryl,

••carbocyclic aryl substituted by halogen,

••heterocyclyl, and

••heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl, and

•••C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy,

•C_{1-5} alkylthio,

•carbocyclic arylthio,

•C_{1-5} alkylsulfonyl,

•carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by halogen,

•carbocyclic arylsulfonyl substituted by C_{1-5} alkyl,

•C_{1-5} alkoxycarbonyl,

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro, and

••C_{1-5} alkyl,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by halogen;

wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;

carbocyclyl is 1-oxo-indanyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, or menthyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-benzopyranyl, 9*H*-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, furyl, isoxazolyl, morpholinyl, oxazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolyl, thienyl, imidazolyl, or piperazyl;

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

4. ***(original):*** The compound according to claim 3 wherein:

R_2 is halogen, C_{1-5} alkyl, C_{1-5} alkoxy, $-N(R_{2a})(R_{2b})$, or heterocyclyl; wherein R_{2a} and R_{2b} are each independently hydrogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by hydroxy, C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{3-6} cycloalkyl, or carbocyclic aryl;

L is selected from the group consisting of Formulae (IIIa) and (IVa);
wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-CH_2-$, or $-(CH_2)_2-$;

Z_1 is hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, C_{1-5} alkoxy, or C_{1-5} alkylthio; Z_2 is hydrogen, halogen, or C_{1-5} alkyl; or
R_2 and Z_2 are bonded to each other to form a ring and $-R_2-Z_2-$ is $-NR_6-CH=CH-$; wherein R_6 is hydrogen or C_{1-5} alkyl; and

Y represents:

(i) $-C(O)NR_5-$, $-C(S)NR_5-$, $-C(O)O-$, $-S(O)_2-$, $-C(O)-$, or $-(CH_2)_m-$ when L is selected from the group consisting of Formula (IIIa); or

(ii) $-C(O)NR_5-$ or $-C(O)O-$ when L is selected from the group consisting of Formula (IVa);

wherein R_5 is hydrogen or C_{1-5} alkyl; and m is 0, 1, or 2;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

5. ***(original):*** The compound according to claim 4 wherein R_1 is selected from the group consisting of:

(i) C_{1-5} alkyl substituted by substituent(s) independly selected from the group consisting of:

•hydroxy,

•carbocyclic aryl,

•carbocyclic aryl substituted by halogen, and

•C_{1-5} alkylthio,

(ii) C_{3-6} cycloalkyl, and

(iii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independly selected from the group consisting of:

•halogen,

•nitro,

•cyano,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by halogen,

•C_{1-5} alkoxy substituted by carbocyclic aryl,

•carbocyclic aryloxy, and

•carbocyclic aryloxy substituted by C_{1-5} alkoxy,

(iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independly selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•carbocyclic aryl, and

•carbocyclic aryl substituted by halogen;

R_2 is $-N(R_{2a})(R_{2b})$ or heterocyclyl; wherein R_{2a} and R_{2b} are each independently hydrogen or C_{1-5} alkyl;

Z_1 is hydrogen, C_{1-5} alkyl, or C_{1-5} alkylthio; Z_2 is hydrogen or C_{1-5} alkyl; or

R_2 and Z_2 are bonded to each other to form a ring and $-R_2-Z_2-$ is $-NR_6-CH=CH-$; wherein R_6 is hydrogen or C_{1-5} alkyl;

L is Formula (IIIa) or (IVa), wherein R_3 and R_4 are hydrogen, A is a single bond and B is a single bond or $-CH_2-$;

and

Y represents:

(i) -C(O)NH-, -C(S)NH, -C(O)-, or $-CH_2-$ when L is selected from the group consisting of Formula (IIIa); or

(ii) -C(O)NH- when L is selected from the group consisting of Formula (IVa);

wherein carbocyclic aryl is phenyl or naphthyl;

heterocyclyl is furyl, 1*H*-indolyl, morpholinyl, oxazolyl, piperidyl, pyridyl, pyrrolidyl, or 9*H*-xanthenyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

6. ***(original):*** The compound according to claim 5 wherein R_1 is selected from the group consisting of:

(i) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independly selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy, and

•C_{1-5} alkoxy substituted by halogen,

(ii) heterocyclyl, and

heterocyclyl substituted by halogen;

and

Z_1 is hydrogen, C_{1-5} alkyl, or C_{1-5} alkylthio; Z_2 is hydrogen or C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl;

heterocyclyl is furyl, pyridyl, or pyrrolidyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

7. ***(original):*** The compound according to claim 1 selected from the group consisting of:

N-(*cis*-4-{[6-(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

4-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-fluorobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,5-difluorobenzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;

3-chloro-4-fluoro-*N*-(*cis*-4-{[2-methyl-6-(methylamino)pyrimidin-4-yl]amino}cyclohexyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-fluorobenzamide;

4-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;

3-chloro-4-fluoro-*N*-{*cis*-4-[(2-methyl-6-piperidin-1-ylpyrimidin-4-yl)amino]cyclohexyl}benzamide;

3-chloro-4-fluoro-*N*-{*cis*-4-[(2-methyl-6-morpholin-4-ylpyrimidin-4-yl)amino]cyclohexyl}benzamide;

3-chloro-4-fluoro-*N*-{*cis*-4-[(7-methyl-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}benzamide;

3,4,5-trifluoro-*N*-{*cis*-4-[(7-methyl-7*H*-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}benzamide;

3,4,5-trifluoro-*N*-(*cis*-4-{[2-methyl-6-(methylamino)pyrimidin-4-yl]amino}cyclohexyl)benzamide;

cis-*N*-(3,4-difluorophenyl)-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexanecarboxamide;

1-(4-chlorophenyl)-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)cyclopentanecarboxamide;

3-(2-chloro-6-fluorophenyl)-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-5-iodo-2-furamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-9*H*-xanthene-9-carboxamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N*'-[1-(1-naphthyl)ethyl]urea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N*'-(3,4,5-trimethoxyphenyl)urea;

N-(5-chloro-2,4-dimethoxyphenyl)-*N*'-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)urea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-(2,4,6-tribromophenyl)urea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-mesitylthiourea;

N-(2,6-diethylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(2,4-dichloro-6-methylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-nitrobenzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-diethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-diethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-isopropoxy-benzamide;

3-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-benzamide;

4-difluoromethoxy-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methyl-benzamide;

3-difluoromethoxy-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

3-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methyl-benzamide;

4-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide;

4-cyano-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methoxy-benzamide;

3-cyano-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-3-methyl-benzamide;

4-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-fluoro-4-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethyl-benzamide;

3-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-fluoro-4-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-trifluoromethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-trifluoromethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid[*cis*-4-(6-dimethylamino- 2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

N-{*cis*-4-[(1*H*-indol-2-ylmethyl)-amino]-cyclohexyl}-2,*N'*,*N'*-trimethyl- pyrimidine-4,6-diamine;

2,*N*,*N*-trimethyl-*N'*-[*cis*-4-(3-trifluoromethoxy-benzylamino)-cyclohexyl]- pyrimidine-4,6-diamine;

N-[*cis*-4-(3,4-difluoro-benzylamino)-cyclohexyl]-2,*N'*,*N'*-trimethyl-pyrimidine-4,6-diamine;

1-(3,4-dimethoxy-phenyl)-3-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-urea;

1-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-(2-ethoxy-phenyl)-urea;

1-(4-benzyloxy-phenyl)-3-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-urea;

3,5-dibromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)- cyclohexyl]-benzamide;

3-bromo-4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;

2-(3,5-bis-trifluoromethyl-phenyl)-*N*-[*cis*-4-(6-dimethylamino-2-methyl- pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-fluoro-4-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-trifluoromethoxy-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-methoxy-benzamide;

4-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)- cyclohexylmethyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-trifluoromethyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3,5-difluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-ethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid [*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-amide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3-fluoro-4-methyl-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-fluoro-benzamide;

3,4-dichloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

4-bromo-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide;

3,5-dichloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

3-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)- cyclohexylmethyl]-4-fluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-fluoro-3-methyl-benzamide; and

3-chloro-*N*-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

8. ***(original):*** The compound according to claim 1 selected from the group consisting of:

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-ethylpyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

3,4-dichloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-5-fluorobenzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3,4,5-trifluorobenzamide;

5-bromo-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)nicotinamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide;

3,5-dichloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

3-chloro-*N*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)benzamide;

3-chloro-4-fluoro-*N*-{*cis*-4-[(2-methyl-6-pyrrolidin-1-ylpyrimidin-4-yl)amino]cyclohexyl}benzamide;

N-(*cis*-4-{[6-(dimethylamino)-2-ethylpyrimidin-4-yl]amino}cyclohexyl)-3,4,5-trifluorobenzamide;

cis-*N*-(3-chloro-4-fluorophenyl)-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexanecarboxamide;

N-(*cis*-4-{[2-benzyl-6-(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-3-chloro-4-fluorobenzamide;

cis-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}-*N*-(3,4,5-trifluorophenyl)cyclohexanecarboxamide;

N-(4-bromo-2,6-dimethylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-*N'*-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)thiourea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-(3,4,5-trimethoxyphenyl)thiourea;

N-(*cis*-4-{[6-(dimethylamino)-2-methylpyrimidin-4-yl]amino}cyclohexyl)-*N'*-(2,4,6-tribromophenyl)thiourea;

5-bromo-furan-2-carboxylic acid [*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

N-[*cis*-4-(3,5-dimethoxy-benzylamino)-cyclohexyl]-2,*N'*,*N'*-trimethyl-pyrimidine-4,6-diamine;

N-[*cis*-4-(3-bromo-benzylamino)-cyclohexyl]-2,*N'*,*N'*-trimethyl-pyrimidine-4,6-diamine;

*1-[*cis-*4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-(3-methoxy-phenyl)-urea;*

1-(3,5-difluoro-phenyl)-3-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexyl]-urea;

N-[*cis*-4-(6-dimethylamino-2-methylsulfanyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-3,5-bis-trifluoromethyl-benzamide; and

N-[*cis*-4-(6-dimethylamino-2-methyl-pyrimidin-4-ylamino)-cyclohexylmethyl]-4-trifluoromethoxy-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

9. ***(original):*** The compound according to claim 2 wherein:

R_1 represents:

(i) hydrogen, $-CO_2{}^tBu$, or $-CO_2Bn$ (Bn is a benzyl group) when L is selected from the group consisting of Formulae (III), (IIIa), and (IIIb); or

(ii) hydrogen, C_{1-5} alkyl, substituted C_{1-5} alkyl, Bn, or substituted Bn when L is selected from the group consisting of Formulae (IV), (IVa), and (IVb);

wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-CH_2-$, or $-(CH_2)_2-$;

R_2 is halogen, C_{1-5} alkyl, C_{1-5} alkoxy, $-N(R_{2a})(R_{2b})$, or heterocyclyl; wherein R_{2a} and R_{2b} are each independently hydrogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by hydroxy, C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{3-6} cycloalkyl, or carbocyclic aryl;

Z_1 is hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, C_{1-5} alkoxy, or C_{1-5} alkylthio; Z_2 is hydrogen, halogen, or C_{1-5} alkyl; or

R_2 and Z_2 are bonded to each other to form a ring and $-R_2-Z_2-$ is $-NR_6-CH=CH-$; wherein R_6 is hydrogen or C_{1-5} alkyl;

and

Y represents:

(i) a single bond when L is selected from the group consisting of Formulae (III), (IIIa), and (IIIb); or

(ii) -C(O)O- when L is selected from the group consisting of Formulae (IV), (IVa), and (IVb);

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

10. ***(original):*** The compound according to claim 9 wherein:

R_1 represents:

(i) hydrogen, $-CO_2{}^tBu$, or $-CO_2Bn$ (Bn is a benzyl group) when L is selected from the group consisting of Formula (IIIa); or

(ii) hydrogen, C_{1-5} alkyl, substituted C_{1-5} alkyl, Bn, or substituted Bn when L is selected from the group consisting of Formula (IVa);

wherein R_3 and R_4 are each hydrogen; and A and B are each independently a single bond or $-CH_2-$;

R_2 is $-N(R_{2a})(R_{2b})$ or heterocyclyl; wherein R_{2a} and R_{2b} are each independently hydrogen or C_{1-5} alkyl;

Z_1 is hydrogen, C_{1-5} alkyl, or C_{1-5} alkylthio; Z_2 is hydrogen or C_{1-5} alkyl; or

R_2 and Z_2 are bonded to each other to form a ring and $-R_2-Z_2-$ is $-NR_6-CH=CH-$; wherein R_6 is hydrogen or C_{1-5} alkyl;

and

Y represents:

(i) a single bond when L is selected from the group consisting of Formula (IIIa); or

(ii) -C(O)O- when L is selected from the group consisting of Formula (IVa);

heterocyclyl is furyl, 1*H*-indolyl, morpholinyl, oxazolyl, piperidyl, pyridyl, pyrrolidyl, or 9*H*-xanthenyl;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

11. ***(original):*** The compound according to claim 1 wherein Q is Formula (IIb);

R_2 is C_{1-5} alkyl substituted by hydroxy, C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by halogenated carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl,

C_{1-5} alkyl substituted by halogenated heterocyclyl, C_{2-5} alkenyl, C_{2-5} alkynyl, or -$N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently hydrogen, C_{1-5} alkyl, or C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

- halogen,
- hydroxy,
- carboxy,
- carbamoyl,
- C_{1-5} alkoxy,
- amino,
- C_{3-6} cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  - halogen,
  - C_{1-5} alkyl,
  - C_{1-5} alkoxy,
  - C_{1-5} alkyl substituted by halogen,
  - C_{1-5} alkoxy substituted by halogen, and
  - -SO_2NH_2,
- heterocyclyl, and
- heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  - halogen,

••C_{1-5} alkyl,

••C_{1-5} alkoxy,

••C_{1-5} alkyl substituted by halogen, and

••C_{1-5} alkoxy substituted by halogen,

carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•C_{1-5} alkoxy,

•C_{1-5} alkyl substituted by halogen, and

•C_{1-5} alkoxy substituted by halogen,

heterocyclyl, or heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl,

•C_{1-5} alkoxy,

•C_{1-5} alkyl substituted by halogen, and

•C_{1-5} alkoxy substituted by halogen;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

12. ***(original):*** The compound according to claim 11 wherein R_1 is selected from the group consisting of:

(i) C_{1-10} alkyl, and

C_{1-10} alkyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•hydroxy,

•oxo,

•C_{1-5} alkoxy,

•C_{1-5} alkoxy substituted by carbocyclic aryl,

•C_{1-5} alkylcarbonyloxy,

•C_{1-5} alkoxycarbonyl,

•C_{1-5} alkoxycarbonyl substituted by carbocyclic aryl,

•carbocyclic aryloxy, and

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by oxo,

•heterocyclyloxy,

•heterocyclyloxy substituted by C_{1-5} alkyl,

•mono-carbocyclic arylamino,

•di-carbocyclic arylamino,

•carbocyclic arylsulfonylamino,

•carbocyclic arylsulfonylamino substituted by C_{1-5} alkyl,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by carbocyclic aryl,

•carbocyclic arylthio,

•carbocyclic arylthio substituted by halogen,

•carbocyclic arylthio substituted by C_{1-5} alkyl,

•carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by halogen,

•heterocyclylthio,

•heterocyclylthio substituted by C_{1-5} alkyl,

•C_{3-6} cycloalkyl,

•C_{3-6} cycloalkenyl,

•carbocyclyl,

•carbocyclyl substituted by C_{1-5} alkoxy,

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••carbocyclic aryl, and

•••heterocyclyl,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by halogen,

••C_{1-5} alkoxy substituted by carbocyclic aryl,

••carbocyclic aryloxy,

••mono-carbocyclic arylaminocarbonyl, and

••mono-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl,

•••C_{1-5} alkoxy, and

•••C_{1-5} alkoxy substituted by halogen,

••di-carbocyclic arylaminocarbonyl, and

••di-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl,

•••C_{1-5} alkoxy, and

•••C_{1-5} alkoxy substituted by halogen,

••C_{1-5} alkylthio,

••C_{1-5} alkylthio substituted by halogen,

••C_{1-5} alkylsulfonyl,

••carbocyclic aryl, and

••heterocyclyl,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••C_{1-5} alkyl,

••C_{1-5} alkoxy,

••C_{1-5} alkoxy substituted by carbocyclic aryl,

••carbocyclic aryl, and

••carbocyclic aryl substituted by halogen,

(ii) C_{2-5} alkenyl, and

C_{2-5} alkenyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••nitro,

••halogen,

••C_{1-5} alkyl,

••C_{1-5} alkyl substituted by halogen,

••C_{1-5} alkoxy, and

••C_{1-5} alkoxy substituted by halogen,

(iii) C_{3-6} cycloalkyl, and

C_{3-6} cycloalkyl substituted by substituent(s) independently selected from the group consisting of:

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by carbocyclic aryl,

•carbocyclic arylcarbonylamino, and

•carbocyclic aryl,

(iv) carbocyclyl, and

carbocyclyl substituted by nitro,

(v) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•cyano,

•nitro,

•C_{1-9} alkyl, and

•C_{1-9} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••oxo,

••mono-carbocyclic arylaminocarbonyl,

••di-carbocyclic arylaminocarbonyl,

••mono-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkoxy,

••di-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkoxy,

••carbocyclic aryloxy,

••carbocyclic aryl, and

••carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl, and

•••C_{1-5} alkyl substituted by halogen,

••heterocyclyl, and

••heterocyclyl substituted by C_{1-5} alkyl,

•C_{2-5} alkenyl,

•C_{1-7} alkoxy,

•C_{1-7} alkoxy substituted by halogen,

•C_{1-7} alkoxy substituted by carbocyclic aryl,

•C_{3-6} cycloalkoxy,

•carbocyclic aryloxy, and

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro, and

••C_{1-5} alkoxy

•heterocyclyloxy, and

•heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxycarbonyl,

•mono-C_{1-5} alkylaminocarbonyl,

•di-C_{1-5} alkylaminocarbonyl,

•mono-C_{1-5} alkylaminocarbonyl substituted by carbocyclic aryl,

•di-C_{1-5} alkylaminocarbonyl substituted by carbocyclic aryl,

•mono-carbocyclic arylaminocarbonyl,

•di-carbocyclic arylaminocarbonyl,

•mono-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkyl,

•di-carbocyclic arylaminocarbonyl substituted by C_{1-5} alkyl,

•mono-C_{1-5} alkylamino,

•di-C_{1-5} alkylamino,

•C_{1-5} alkylthio,

•C_{1-5} alkylthio substituted by halogen,

•C_{1-5} alkylsulfonyl,

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••C_{1-7} alkyl, and

••C_{1-7} alkyl substituted by halogen,

(vi) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•halogen,

•C_{1-5} alkyl, and

•C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••oxo,

••carbocyclic aryl,

••carbocyclic aryl substituted by halogen,

••heterocyclyl, and

••heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

•••halogen,

•••C_{1-5} alkyl, and

•••C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy,

•C_{1-5} alkylthio,

•carbocyclic arylthio,

•C_{1-5} alkylsulfonyl,

•carbocyclic arylsulfonyl,

•carbocyclic arylsulfonyl substituted by halogen,

•carbocyclic arylsulfonyl substituted by C_{1-5} alkyl,

•C_{1-5} alkoxycarbonyl,

•carbocyclic aryl, and

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••nitro, and

••C_{1-5} alkyl,

•heterocyclyl, and

•heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C_{1-5} alkyl, and

••C_{1-5} alkyl substituted by halogen;

wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;

carbocyclyl is 1-oxo-indanyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, or menthyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-benzopyranyl, 9*H*-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, furyl, isoxazolyl, morpholinyl, oxazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl;

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

13. ***(original):*** The compound according to claim 12 wherein:

R_2 is C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by halogenated carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{1-5} alkyl substituted by halogenated heterocyclyl, carbocyclic aryl, carbocyclic aryl by halogen, heterocyclyl, heterocyclyl by halogen, or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently

hydrogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by hydroxy, or C_{1-5} alkyl substituted by halaogen;

L is Formula (IIIa); wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-CH_2-$, or $-(CH_2)_2-$;

Z_3 and Z_4 are each independently hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, mono-C_{1-5} alkyl amino, or di-C_{1-5} alkyl amino;

and

Y is $-C(O)-$, $-C(O)NR_5-$, $-C(S)NR_5-$, or $-(CH_2)_m-$; wherein R_5 is hydrogen or C_{1-5} alkyl; and m is 0, 1, or 2; Y is not $-(CH_2)_m-$ provided that either R_{2a} or R_{2b} is hydrogen;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

14. ***(original):*** The compound according to claim 13 wherein R_1 is selected from the group consisting of:

(i) C_{1-5} alkyl substituted by substituent(s) independly selected from the group consisting of:

•hydroxy,

•carbocyclic aryl,

•carbocyclic aryl substituted by halogen, and

•carbocyclic aryl substituted by halogenated C_{1-5} alkyl,

(ii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independly selected from the group consisting of:

•halogen,

•cyano,

•C_{1-5} alkyl,

•C_{1-5} alkyl substituted by halogen,

•C_{1-5} alkoxy, and

•C_{1-5} alkoxy substituted by halogen,

(iii) heterocyclyl, and

heterocyclyl substituted by halogen;

R_2 is C_{1-5} alkyl substituted by carbocyclic aryl or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently hydrogen or C_{1-5} alkyl;

L is Formula (IIIa); wherein R_3 and R_4 are each hydrogen; and A and B are each a single bond;

Z_3 and Z_4 are each independently hydrogen, C_{1-5} alkyl, mono-C_{1-5} alkyl amino, or di-C_{1-5} alkyl amino;

and

Y is -C(O)-;

wherein carbocyclic aryl is phenyl;

heterocyclyl is furyl or pyridyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

15. ***(original):*** The compound according to claim 14 wherein R_1 is selected from the group consisting of:

carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independly selected from the group consisting of:

•halogen,

•cyano, and

•C_{1-5} alkoxy;

Z_3 is hydrogen when Z_4 is C_{1-5} alkyl; or Z_3 is C_{1-5} alkyl, mono-C_{1-5} alkyl amino, or di-C_{1-5} alkyl amino when Z_4 is hydrogen;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

16. ***(original):*** The compound according to claim 1 selected from the group consisting of:

3-chloro-*N*-(*cis*-4-{[2-(dimethylamino)-6-methylpyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(*cis*-4-{[2-(dimethylamino)-6-methylpyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-methoxy-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid [*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

4-cyano-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-chloro-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;

5-bromo-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-nicotinamide;

5-bromo-furan-2-carboxylic acid [*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

3,5-dibromo-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)- cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

2-(3,5-bis-trifluoromethyl-phenyl)-*N*-[*cis*-4-(2-dimethylamino-5-methyl- pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

2-(4-bromo-phenyl)-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-diethoxy-benzamide;

3-bromo-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide;

2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid [*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

4-chloro-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethyl-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-methyl-benzamide;

5-bromo-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-nicotinamide;

5-bromo-furan-2-carboxylic acid [*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-amide;

3,5-dibromo-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)- cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3-ethoxy-benzamide;

2-(3,5-bis-trifluoromethyl-phenyl)-*N*-[*cis*-4-(2-dimethylamino-6-methyl- pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

2-(4-bromo-phenyl)-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-2-hydroxy-acetamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-diethoxy-benzamide; and

3-bromo-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-4-fluoro-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

17. ***(original):*** The compound according to claim 1 selected from the group consisting of:

3-chloro-*N*-(*cis*-4-{[2-(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(*cis*-4-{[2,6-bis(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-3,4-difluorobenzamide;

N-(*cis*-4-{[2-benzyl-6-(dimethylamino)pyrimidin-4-yl]amino}cyclohexyl)-3-chloro-4-fluorobenzamide;

3,4-dichloro-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

4-cyano-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-diethoxy-benzamide;

3-chloro-*N*-[*cis*-4-(2-dimethylamino-6-methyl-pyrimidin-4-ylamino)-cyclohexyl]-5-fluoro-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide;

3,4-dichloro-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-benzamide;

N-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-3,4-diethoxy-benzamide; and

3-chloro-*N*-[*cis*-4-(2-dimethylamino-5-methyl-pyrimidin-4-ylamino)-cyclohexyl]-5-fluoro-benzamide;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

18. ***(original):*** The compound according to claim 11 wherein:

R_1 is selected from hydrogen, $-CO_2{}^tBu$, or $-CO_2Bn$ (Bn is a benzyl group);

R_2 is C_{1-5} alkyl substituted by carbocyclic aryl, C_{1-5} alkyl substituted by halogenated carbocyclic aryl, C_{1-5} alkyl substituted by heterocyclyl, C_{1-5} alkyl substituted by halogenated heterocyclyl, carbocyclic aryl, carbocyclic aryl by halogen, heterocyclyl, heterocyclyl by halogen, or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently hydrogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by hydroxy, or C_{1-5} alkyl substituted by halaogen;

L is Formula (IIIa); wherein R_3 and R_4 are each independently hydrogen or C_{1-5} alkyl; and A and B are each independently a single bond, $-CH_2-$, or $-(CH_2)_2-$;

Z_3 and Z_4 are each independently hydrogen, halogen, C_{1-5} alkyl, C_{1-5} alkyl substituted by halogen, mono-C_{1-5} alkyl amino, or di-C_{1-5} alkyl amino; and

Y is a single bond;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

19. ***(original):*** The compound according to claim 18 wherein:

R_2 is C_{1-5} alkyl substituted by carbocyclic aryl or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are each independently hydrogen or C_{1-5} alkyl;

L is Formula (IIIa); wherein R_3 and R_4 are each hydrogen; and A and B are each a single bond; and

Z_3 and Z_4 are each independently hydrogen, C_{1-5} alkyl, mono-C_{1-5} alkyl amino, or di-C_{1-5} alkyl amino;

wherein carbocyclic aryl is phenyl;

heterocyclyl is furyl or pyridyl;

halogen is fluoro, chloro, or bromo;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

20. ***(original):*** A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 19 in combination with a pharmaceutically acceptable carrier.

21. ***(currently amended):*** A method for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from said condition a therapeutically effective amount of

a compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1.

22. ***(currently amended):*** A method for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1.

23. ***(currently amended):*** A method for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1.

24. ***(currently amended):*** A compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1 for use in a method of treatment of the human or animal body by therapy.

25. ***(currently amended):*** A compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~ claim 1for use in a method of prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by therapy.

26. ***(currently amended):*** A compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1 for use in a method of prophylaxis or treatment of

anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body by therapy.

27. ***(currently amended):*** A compound according to ~~any one of claims 1 to 19~~claim 1 for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.

28. ***(currently amended):*** A compound according to ~~any one of claims 1 to 19~~claim 1 for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

29. ***(currently amended):*** A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1.

30. ***(currently amended):*** A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1.

31. ***(currently amended):*** A method of controlling or reducing weight gain in an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims 1 to 19 or a pharmaceutical composition according to claim 20~~claim 1.

32. ***(currently amended):*** A method of modulating a MCH receptor in an individual comprising contacting the receptor with a compound according to ~~any one of claims 1 to 19~~claim 1.

33. ***(original):*** The method of modulating the MCH receptor according to claim 32 wherein the compound is an antagonist.

34. ***(original):*** The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor is for the prophylaxis or treatment of an eating disorder, obesity or obesity related disorder.

35. ***(original):*** The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor reduces food intake of the individual.

36. ***(original):*** The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor induces satiety in the individual.

37. ***(original):*** The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor controls or reduces weight gain of the individual.

38. ***(original):*** The method of modulating the MCH receptor according to claims 32 or 33 wherein the modulation of the MCH receptor is for prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

39. ***(currently amended):*** The method of modulating the MCH receptor according to any one of claims ~~22, 23 and 29 to 38~~32 or 33 wherein the individual is a mammal.

40. ***(original):*** The method of modulating the MCH receptor according to claim 39 wherein the mammal is a human.

41. ***(original):*** The method according to claim 40 wherein the human has a body mass index of about 18.5 to about 45.

42. ***(original):*** The method according to claim 41 wherein the human has a body mass index of about 25 to about 45.

43. ***(original):*** The method according to claim 42 wherein the human has a body mass index of about 30 to about 45.

44. ***(original):*** The method according to claim 43 wherein the human has a body mass index of about 35 to about 45.

45. ***(currently amended):*** A method of producing a pharmaceutical composition comprising admixing a compound according to ~~any one of claims 1 to 19~~claim 1 and a pharmaceutically acceptable carrier.